406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies

by Laura Vitale, Michael Yellin, Li-Zhen He, Lawrence Thomas, Tracey Rawls, Diane Young, Philip Golden
Published 2020-11-01